查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1800209

主動式植入式醫療設備(AIMD) 市場 - 2025 年至 2030 年預測

Active Implantable Medical Devices (AIMD) Market - Forecasts fom 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

主動植入式醫療設備(AIMD) 市場預計將從 2025 年的 351.95 億美元成長到 2030 年的 491.97 億美元，複合年成長率為 6.93%。

受技術進步、人口老化和慢性病盛行率上升的推動，全球有源植入式醫療設備(AIMD) 市場正在經歷顯著成長。心律調節器和神經刺激設備等 AIMD 對於監測和治療疾病至關重要，尤其對於老年人。

市場促進因素

1. 老化社會中慢性病盛行率上升：老年人中心血管疾病、糖尿病和神經系統疾病等慢性病盛行率的上升是AIMD市場的主要驅動力。這些設備在管理複雜的醫療保健需求、改善患者預後和提高生活品質方面發揮著至關重要的作用。全球老年人口的成長推動了對AIMD的需求，醫療保健提供者正在尋求先進的解決方案來應對與老齡化相關的健康挑戰。

2. 技術進步與人工智慧整合：AIMD 技術的創新，例如將人工智慧 (AI) 整合用於患者專屬診斷，正在推動市場成長。 AI 設備正在提高監測準確性和治療效果，促進其廣泛應用。持續的研發和現有 AIMD 適應症的擴展，進一步推動了技術創新，為市場持續成長奠定了基礎。

3. 政府政策與資金支持：韓國《醫療設備產業培育及創新醫療設備扶持法》等監管架構正在促進AIMD的發展。政府資金以及人們對AIMD益處的認知度不斷提升，推動了AIMD研發和產品上市的投資，從而支持了市場擴張。

市場限制

1.高成本和監管挑戰：AIMD 的開發和製造成本高昂，加上嚴格的監管要求，對市場成長構成挑戰。遵守不同的全球標準會增加製造成本和時間，這可能會限制其在成本敏感型市場的普及。

2. 新興市場認知度低：儘管需求不斷成長，但某些地區（尤其是新興經濟體）對AIMD益處的認知度較低，這可能會阻礙市場滲透。向醫療保健專業人員和患者普及AIMD的益處仍然是一項重大挑戰。

區域展望

  • 北美（美國）：受心血管疾病高發生率的推動，美國預計將佔據最大的市場佔有率。根據世界銀行的數據，到2022年，老齡化人口將占美國總人口的17%，這將進一步推動對AIMD的需求。雅培實驗室的AVEIR™雙腔心律調節器（已於2023年7月獲得FDA核准）等技術進步將透過提供針對心律不整的創新解決方案來推動市場成長。
  • 亞太地區：在印度等慢性病負擔沉重的國家（根據美國國家醫學圖書館的數據，21% 的老年人受慢性病影響），對AIMD的需求正在增加。支持性法律規範和醫療基礎設施投資正在推動該地區的成長。

關鍵發展（2023-2025年）

  • 2023 年 7 月：雅培實驗室的 AVEIR™ 雙腔心律調節器獲得美國FDA核准，擴大了美國心率患者的治療選擇。

市場展望

預計到2025年，AIMD市場將迎來強勁成長，這得益於慢性病負擔的增加、技術進步以及扶持政策的推動。美國由於人口老化和疾病高發生率而引領市場，但亞太地區也蘊藏著巨大的潛力。為了保持成長，需要應對高成本和監管複雜性等挑戰。預計產業參與者將專注於整合人工智慧並產品推出，以滿足不斷變化的醫療保健需求。

本報告的主要優點

  • 深刻分析：獲得深入的市場洞察，重點關注客戶細分、政府政策和社會經濟因素、消費者偏好、垂直行業和其他細分市場，涵蓋主要地區和新興地區。
  • 競爭格局：了解主要企業採用的策略策略，並了解正確策略的市場滲透潛力。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力進行策略決策並在動態環境中開闢新的業務流和收益。
  • 適合廣泛的使用者：對於新興企業、研究機構、顧問、中小企業和大型企業來說都是有益且具有成本效益的。

它有什麼用途？

產業與市場考量、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

調查範圍

  • 2020 年至 2024 年的歷史數據和 2025 年至 2030 年的預測數據
  • 成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 收益成長和預測細分市場和區域分析（包括國家）
  • 公司概況（尤其是趨勢）、財務資訊和關鍵發展。

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 經營狀況

  • 市場促進因素
  • 市場限制
  • 市場機會
  • 波特五力分析
  • 產業價值鏈分析
  • 政策法規
  • 策略建議

第4章 技術展望

5. 主動式植入式醫療設備(AIMD) 市場（依產品）

  • 介紹
  • 心室輔助裝置
  • 神經刺激設備
  • 植入式心臟節律器
  • 人工電子耳
  • 其他

6. 主動式植入式醫療設備(AIMD) 市場（依最終用戶）

  • 介紹
  • 醫院和診所
  • 門診手術中心
  • 專業中心
  • 居家照護環境

7. 主動式植入式醫療設備(AIMD) 市場（按地區）

  • 介紹
  • 北美洲
    • 按產品
    • 按最終用戶
    • 按國家
      • 美國
      • 加拿大
      • 墨西哥
  • 南美洲
    • 按產品
    • 按最終用戶
    • 按國家
      • 巴西
      • 阿根廷
      • 其他
  • 歐洲
    • 按產品
    • 按最終用戶
    • 按國家
      • 英國
      • 德國
      • 法國
      • 西班牙
      • 其他
  • 中東和非洲
    • 按產品
    • 按最終用戶
    • 按國家
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 其他
  • 亞太地區
    • 按產品
    • 按最終用戶
    • 按國家
      • 中國
      • 日本
      • 印度
      • 韓國
      • 台灣
      • 其他

第8章競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第9章：公司簡介

  • Sonova Holding AG
  • Medtronic
  • Abbott
  • Lifetech Scientific
  • Boston Scientific Corporation
  • Cochlear Ltd.
  • MED-EL
  • Biotronik SE & Co. KG
  • LivaNova PLC

第10章 附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061611637

The Active Implantable Medical Devices (AIMD) Market is expected to grow from USD 35.195 billion in 2025 to USD 49.197 billion in 2030, at a CAGR of 6.93%.

The global active implantable medical devices (AIMD) market is experiencing significant growth, driven by technological advancements, an aging population, and the rising prevalence of chronic diseases. AIMDs, such as pacemakers and neurostimulators, are critical for monitoring and treating conditions, particularly in geriatric patients.

Market Drivers

1. Rising Prevalence of Chronic Diseases in the Aging Population: The growing incidence of chronic conditions, such as cardiovascular diseases, diabetes, and neurological disorders, among older adults is a primary driver of the AIMD market. These devices play a vital role in managing complex healthcare needs, improving patient outcomes, and enhancing quality of life. The increasing elderly population globally amplifies demand for AIMDs, as healthcare providers seek advanced solutions to address age-related health challenges.

2. Technological Advancements and AI Integration: Innovations in AIMD technology, including the integration of artificial intelligence (AI) for patient-specific diagnostics, are propelling market growth. AI-enabled devices enhance monitoring precision and treatment efficacy, driving adoption. Ongoing research and development, along with expanded indications for existing AIMDs, further fuel innovation, positioning the market for sustained growth.

3. Supportive Government Policies and Funding: Regulatory frameworks, such as the Republic of Korea's Act on Fostering the Medical Devices Industry and Supporting Innovative Medical Devices, are fostering AIMD development. Government funding and increased awareness of AIMD benefits are encouraging investment in research and product launches, supporting market expansion.

Market Restraints

1. High Costs and Regulatory Challenges: The high cost of developing and manufacturing AIMDs, coupled with stringent regulatory requirements, poses challenges to market growth. Compliance with diverse global standards increases production costs and timelines, potentially limiting accessibility in cost-sensitive markets.

2. Limited Awareness in Emerging Markets: Despite growing demand, limited awareness of AIMD benefits in certain regions, particularly in developing economies, may hinder market penetration. Educating healthcare providers and patients about the advantages of AIMDs remains a critical challenge.

Geographical Outlook

  • North America (United States): The U.S. is expected to hold the largest market share, driven by the high prevalence of cardiovascular diseases. The aging population, representing 17% of the U.S. population in 2022 per World Bank data, further boosts demand for AIMDs. Technological advancements, such as Abbott Laboratories' FDA-approved AVEIR(TM) dual-chamber pacemaker in July 2023, enhance market growth by offering innovative solutions for heart rhythm disorders.
  • Asia-Pacific: Countries like India, with a high burden of chronic diseases (21% of the elderly affected, per the National Library of Medicine), are seeing increased demand for AIMDs. Supportive regulatory frameworks and investments in healthcare infrastructure are driving growth in this region.

Key Developments (2023-2025)

  • July 2023: Abbott Laboratories received U.S. FDA approval for its AVEIR(TM) dual-chamber pacemaker, expanding treatment options for patients with abnormal heart rhythms in the U.S.

Market Outlook

The AIMD market is poised for robust growth through 2025, driven by the rising burden of chronic diseases, technological advancements, and supportive policies. The U.S. leads due to its aging population and high disease prevalence, while Asia-Pacific shows strong potential. Challenges such as high costs and regulatory complexities must be addressed to sustain growth. Industry players are expected to focus on AI integration and innovative product launches to meet evolving healthcare demands.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2020 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Active Implantable Medical Devices (AIMD) Market Segmentation:

By Product

  • Ventricular Assist Devices
  • Neurostimulators
  • Implantable Cardiac Pacemakers
  • Cochlear Implants
  • Others

By End-User

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Specialty Centers
  • Home Care Settings

By Geography

  • North America
  • South America
  • Europe
  • Middle East and Africa
  • Asia Pacific

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. ACTIVE IMPLANTABLE MEDICAL DEVICES (AIMD) MARKET BY PRODUCT

  • 5.1. Introduction
  • 5.2. Ventricular Assist Devices
  • 5.3. Neurostimulators
  • 5.4. Implantable Cardiac Pacemakers
  • 5.5. Cochlear Implants
  • 5.6. Others

6. ACTIVE IMPLANTABLE MEDICAL DEVICES (AIMD) MARKET BY END-USER

  • 6.1. Introduction
  • 6.2. Hospitals & Clinics
  • 6.3. Ambulatory Surgical Centers
  • 6.4. Specialty Centers
  • 6.5. Home Care Settings

7. ACTIVE IMPLANTABLE MEDICAL DEVICES (AIMD) MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Product
    • 7.2.2. By End-User
    • 7.2.3. By Country
      • 7.2.3.1. USA
      • 7.2.3.2. Canada
      • 7.2.3.3. Mexico
  • 7.3. South America
    • 7.3.1. By Product
    • 7.3.2. By End-User
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
      • 7.3.3.2. Argentina
      • 7.3.3.3. Others
  • 7.4. Europe
    • 7.4.1. By Product
    • 7.4.2. By End-User
    • 7.4.3. By Country
      • 7.4.3.1. United Kingdom
      • 7.4.3.2. Germany
      • 7.4.3.3. France
      • 7.4.3.4. Spain
      • 7.4.3.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. By Product
    • 7.5.2. By End-User
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
      • 7.5.3.2. UAE
      • 7.5.3.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. By Product
    • 7.6.2. By End-User
    • 7.6.3. By Country
      • 7.6.3.1. China
      • 7.6.3.2. Japan
      • 7.6.3.3. India
      • 7.6.3.4. South Korea
      • 7.6.3.5. Taiwan
      • 7.6.3.6. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Sonova Holding AG
  • 9.2. Medtronic
  • 9.3. Abbott
  • 9.4. Lifetech Scientific
  • 9.5. Boston Scientific Corporation
  • 9.6. Cochlear Ltd.
  • 9.7. MED-EL
  • 9.8. Biotronik SE & Co. KG
  • 9.9. LivaNova PLC

10. APPENDIX

  • 10.1. Currency
  • 10.2. Assumptions
  • 10.3. Base and Forecast Years Timeline
  • 10.4. Key Benefits for the Stakeholders
  • 10.5. Research Methodology
  • 10.6. Abbreviations